Conatus Pharmaceuticals, Inc.

ACTIVE

加利福尼亚州圣迭戈县, California, United Stateswww.conatuspharma.comPublic11–50 employeesEstablished: 2005-01-01

Part of Histogen, Inc.

Clinical Trials

5 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2005

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

63.6%

Phase 1

31.8%

Trial Status Distribution

Active, not recruiting

22.7%

Completed

54.5%

Terminated

18.2%

Unknown

4.5%

Clinical Trials

Trials sponsored by this organization (22)

Post-Treatment Follow-up Study for Liver Disease Subjects With or Without Cirrhosis After Receiving Emricasan or Placebo

Terminated

observational

Feb 201840 participants

Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

Phase 2

Unknown

interventional

Jun 2017210 participants

A multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of definite NASH” with cirrhosis and severe portal hypertension.

Phase 1

Active, not recruiting

Oct 2016240 participants

A multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of definite NASH” with cirrhosis and severe portal hypertension.

Phase 1

Active, not recruiting

Aug 2016240 participants

A multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of definite NASH” with cirrhosis and severe portal hypertension.

Phase 1

Active, not recruiting

Aug 2016240 participants

A multicenter, double-blind, randomized, placebo-controlled trial involving subjects with a diagnosis of ?definite NASH? with fibrosis (excluding cirrhosis).

Phase 1

Active, not recruiting

Mar 2016330 participants

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

Phase 2

Completed

interventional

Jan 2016318 participants

A Study of IDN-6556 in Cirrhotic Subjects With Portal Hypertension

Phase 2

Completed

interventional

Aug 201423 participants

Page 1 of 3

Approvals

No approval data available

News

No news articles found

Back to Organizations